Poster Session B

Poster Session B
Tuesday, July 13
4:00 p.m.-6:00 p.m.

Subject to change (in alphabetical order, not board assignment order)

A high-throughput allelic copy-number platform utilizing a 75-ng DNA input in a 330,000 Molecular Inversion Probes (MIP) assay on microarrays with FFPE samples. Yuker Wang, Ron Sapolsky, Jen Wilkins, Victoria Carlton, Farooq Siddiqui, Tom Asbury. Affymetrix, Santa Clara, CA.
A New Class of Diazonamide Analogs with Improved Anti-Tumor Activity. Lin Li1, Qi Wei1, Ming Zhou1, Vijayashree Ramesh1, Xiaodong Wang2, Patrick G. Harran3, Lai Wang1. 1Joyant Pharmaceuticals, Dallas, TX, 2Howard Hughes Medical Institute, Dallas, TX, 3University of California, Los Angeles, CA.
A new resource to accelerate research into the cause and prevention of breast cancer: The Love/Avon Army of Women. Susan Love, Leah Wilcox. Dr. Susan Love Research Foundation, Santa Monica, CA.
A requirement for p63 function in Squamous Cell Carcinoma in vivo: Can the pathway be targeted for therapy? Matthew R. Ramsey1, Catherine Wilson1, William C. Faquin2, Alea A. Mills3, Leif W. Ellisen1. 1Massachusetts General Hospital Cancer Center/Harvard Medical School, Boston, MA, 2Massachusetts General Hospital Department of Pathology, Boston, MA, 3Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
Alterations of p53, PTEN and EGFR genes in glioblastoma multiforme. Jasna Bankovic1, Vedrana Milinkovic1, Miodrag Rakic2, Milos Jokovic2, Tijana Andjelkovic1, Ana Podolski-Renic1, Nikola Tanic1, Sabera Ruzdijic1. 1University of Belgrade, Institute for Biological Research Sinisa Stankovic, Belgrade, Serbia, 2University of Belgrade Institute for Neurosurgery, Clinical Centre of Serbia, Belgrade, Serbia.
Altered response to the prodrug of gemcitabine LY2334737 by overexpression or knockdown of carboxylesterase 2 (CES2). Sara Durland-Busbice, Susan E. Pratt, Robert L. Shepard, Philip W. Iversen, Lisa Kays, Darryl Ballard, Kathleen Heinz-Taheny, Anne H. Dantzig. Eli Lilly & Co., Indianapolis, IN.
An empirical evaluation of array normalization for Agilent microRNA expression arrays. Li-Xuan Qin, Jaya Satagopan, Samuel Singer. Memorial Sloan-Kettering Cancer Center, New York, NY.
Characterizing the MDSCs phenotypes, expansion and trafficking pattern and associated tumor-induced immune dysfunction. Ibrahim Hamdy Younos, Traci Hoke, Alicia Dafferner, Holly Samson, Moses Donkor, Sherry Westphal, James E. Talmadge. University of Nebraska Medical Center, Omaha, NE.
Chromosome 17p13.1 (KCTD11), a smoking-related susceptible region linked to lung cancer risk in Korean populations. Yeiwon Lee, Minhyeok Lee, Hyunjung Cho, Jeeyoung Hong, Seonjung Kwon, Chang-Gyo Park, Hoi-Young Lee, Ji-Woong Son, Jaeku Kang, Jeeyoung Hong. Konyang University, Daejeon, Republic of Korea.
Comparative proteomic analysis of colorectal cell lines to identify biomarkers for the prediction of intrinsic resistance to FOLFOX chemotherapy. Florian T. Unger, Markus Meyer, Monika Spörl, Agnieszka Harasym, Kevin Sullivan, Hartmut Juhl, Kerstin A. David. Indivumed GmbH, Hamburg, HH, Germany.
Complete characterization of the "microRNAome" of a human acute myeloid leukemia. Giridharan Ramsingh, Daniel C. Koboldt, Maria Trissal, Katherine B. Chiappinelli, Todd Wylie, Sunita Koul, Li-Wei Chang, Rakesh Nagarajan, Todd A. Fehniger, Paul Goodfellow, Vincent Magrini, Richard K. Wilson, Li Ding, Timothy J. Ley, Elaine R. Mardis, Daniel C. Link. Washington University, St. Louis, MO.
Correlation of the expression of hepcidin mRNA and the serum iron, ferritin and TIBC levels in hepatocellular carcinoma. Smita C. Pawar. Osmania University, Hyderabad, Andhra Pradesh, India. *Unable to present poster due to unforeseen circumstances.
Critical prognostic genes for stage I lung adenocarcinoma are identified from normal growth factor-signaling system by overcoming cancer heterogeneity. Noriko Gotoh1, Mai Yamauchi1, Rui Yamaguchi1, Masao Nagasaki1, Teppei Shimamura1, Seiya Imoto1, Takashi Khono2, Jun Yokota2, David G. Beer3, Satoru Miyano1. 1Institute of Medical Scinece, University of Tokyo, Tokyo, Japan, 2National Cancer Center Research Institute, Tokyo, Japan, 3University of Michigan, Ann Arbor, MI.
Cytotoxic Effect of 21kDa Protein and Antitumor Effect of 31KDa Protein Derived from Mushroom, Schizophyllum commune. Yu-Sheng Wu, Po-Yen Chang, Su-Nan Chen. National Taiwan University, Taipei, Taiwan.
Differences in expression of Hedgehog-Gli intermediates allow to classify astrocytic tumours and tumour stem cells in subgroups and are related to important clinical characteristics. Maria Peris-Celda1, Miriam Romaguera-Ros2, Pepa Carrión-Navarro2, Jorge Oliver de La Cruz2, Jose Manuel Garcia-Verdugo2, Angel Ayuso-Sacido2. 1Principe Felipe Research Center, La Fe University Hospital, Valencia, Spain, 2Principe Felipe Research Center, Valencia, Spain.
Dominant stablized β-catenin induces adenomyosis formation and ablation of Mig-6 accelerates progress of adenomyosis formation. Jung-Ho Shin1, Tae Hoon Kim2, Michael J. Large2, Sung Nam Cho2, Seo Jin Oh3, Jeong Mook Lim3, Makoto M. Taketo4, Russell R. Broaddus5, Jae-Wook Jeong2. 1Korea University Medical Center, Seoul, Republic of Korea, 2Baylor College of Medicine, Houston, TX, 3Seoul National University, Seoul, Republic of Korea, 4Kyoto University, Kyoto, Japan, 5UT M. D. Anderson Cancer Center, Houston, TX.
Ex vivo prostate cancer organ culture: Development and validation of an experimental model system to test novel targeted therapies in prostate cancer and offer a patient-tailored approach. Shilpa Gupta, Lei Gu, Zhiyong Liao, Peter Mc Cue, Edourd J. Trabulsi, Marja T. Nevalainen. Thomas Jefferson University, Philadelphia, PA. *Unable to present poster due to unforeseen circumstances.
Expression of CTIP2/Bcl11b is linked to disease progression in head and neck cancer and is a critical mediator of epithelial cell migration and motility during wound healing processes. Gaurav Bajaj, Jang Hyo-Sang, Talicia Savage, Xiaobo Liang, Mark Leid, Arup Indra, Gitali Ganguli-Indra. Oregon State University, Corvallis, OR.
Genetic interactions between AKT/mTOR and Ras/MAPK pathways in liver cancer pathogenesis: from animal models to targeted therapy. Xin Chen1, Coral Ho1, Chunmei Wang1, Susie Lee1, Matthias Evert2, Frank Dombrowski2, Diego Calvisi2. 1UCSF, San Francisco, CA, 2Ernst-Moritz-Arndt-Universität, Greifswald, Germany.
Genetic profiling reveals cross-contamination and misidentification of 6 Adenoid cystic carcinam cell lines. Janyaporn Phuchareon1, Yoshihito Otha1, Jonathan M. Woo2, David W. Eisele3, Osamu Tetsu3. 1 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, 2UCSF Genomic Core Facility, San Francisco, CA, 3UCSF Otolaryngology-HNS, San Francisco, CA.
Genetic variation in DNA repair pathway genes and melanoma risk. Mingfeng Zhang, Abrar Qureshi, Qun Guo, Jiali Han. Brigham and Women’s Hospital, Boston, MA.
Genome-wide analysis of CpG methylation for the radiosensitivity. Eun-Hye Kim1, Ae-Kyung Park1, Jung-Hyuck Ahn2, Woong-Yang Park1. 1Seoul National University College of Medicine, Seoul, Republic of Korea, 2Ewha Womans University College of Medicine, Seoul, Republic of Korea.
Genomic characterization of triple negative breast cancers with high-resolution SNP 6.0 Affymetrix arrays. Emanuele de Rinaldis, Anita Grigoriadis, Mamunur Rashid, Patrycja Gazinska, Leticia Bosshard-Carter, Elodie Noel, Cheryl Gillett, Pierfrancesco Marra, Andrew Tutt. Kings College London, School of Medicine, London, United Kingdom.
High throughput cell line profiling for identification of anticancer drug sensitivity and resistance biomarkers with OncoPredictor. C. O’Day1, Y. Ovechkina1, K. Marcoe1, R. Keyser1, K. Yoshino1, P. Nguyen1, J. Hnilo1, R. Shively1, J. Mulligan1, K. Bernards1, T. Lin1, S. Wang1, S. Sadis2, D. R. Rhodes2, W. Warrior1. 1Ricerca Biosciences, Bothell, WA, 2Compendia Bioscience, Ann Arbor, MI.
Identification of carboxylesterase 2 as a hydrolase that cleaves the prodrug of gemcitabine LY2334737. Susan E. Pratt, Sara Durland-Busbice, Robert L. Shepard, Harry B. Harlow, Darryl Ballard, Kathleen M. Heinz-Taheny, Anne H. Dantzig. Lilly Research Laboratories, Indianapolis, IN.
Identification of kinases that compensate for PI3K inhibition in breast cancer cells. Ariella B. Hanker, Anindita Chakrabarty, Carlos L. Arteaga. Vanderbilt University, Nashville, TN.
Identification of novel mutations in the inhibitory adaptor protein LNK in patients with JAK2 V617F-negative and -positive chronic myeloproliferative neoplasms. Stephen T. Oh, Jacob M. Zahn, Erin F. Simonds, John Bell, Georges Natsoulis, Jason Buenstro, Carol Jones, Matthew B. Hale, Yury Goltsev, Kenneth D. Gibbs, Jr., Jason D. Merker, James L. Zehnder, Ronald W. Davis, Garry P. Nolan, Hanlee P. Ji, Jason Gotlib. Stanford University School of Medicine, Stanford, CA.
Immunohistochemistry and RT-PCR evaluation of fixative effects in a model tissue system. Carl Millward, Mei-Lan Liu, Jennie Jeong, Ranjana Ambannavar, Hargita Kaplan, Francois Collin, Joffre Baker, Maureen Cronin. Genomic Health, Inc., Redwood City, CA.
Indigeneously synthesized inorganic coordination complex act as apoptotic agent in cancerous cells. Payel Banerjee1, Paramita Majumder2, Santasree Mazumder1. 1University of Calcutta, Kolkata, West Bengal, India, 2Jadavpur University, Kolkata, West Bengal, India.
Inhibition of lung cancer cell invasion by siRNAs delivered by cell-specific aptamers. Wei-Ya Wang, Wei-Yun Lai, Tzu-Hung Hsiao, Konan Peck. Academia Sinica, Taipei, Taiwan.
Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a novel prodrug activator gene transfer technology in an immune-competent model of glioblastoma. Derek Ostertag1, Karin Amundson1, Taylor Buckley1, Fernando E. Lopez1, Bryan Martin1, Harry Gruber1, Walter Gunzburg2, Omar Perez1, Douglas J. Jolly1, Joan M. Robbins1. 1Tocagen, Inc., San Diego, CA, 2Institute of Virology, Vienna, Austria.
Modeling cancer alleles in the genome of human cells to identify the molecular basis of drug response. Sabrina Arena1, Federica Di Nicolantonio1, Josep Tabernero2, Stefano Grosso3, Francesca Molinari4, Teresa Macarulla2, Mariangela Russo1, Carlotta Cancelliere1, Davide Zecchin1, Luca Mazzucchelli4, Takehiko Sasazuki5, Senji Shirasawa6, Massimo Geuna7, Milo Frattini4, José Baselga2, Margherita Gallicchio8, Stefano Biffo3, Alberto Bardelli1. 1Institute for Cancer Research and Treatment, Candiolo, Torino, Italy, 2Vall d’Hebron University Hospital, Barcelona, Spain, 3San Raffaele Scientific Institute, Milano, Italy, 4Istituto Cantonale di Patologia, Locarno, Switzerland, 5International Medical Center of Japan, Shinjuku, Tokyo, Japan, 6School of Medicine, Fukuoka University, Fukuoka, Japan, 7Ospedale Mauriziano Umberto I, Torino, Italy, 8University of Turin, Torino, Italy.
Molecular and cytogenetic characterization of novel multidrug resistant human tumor cell lines. Sabera Ruzdijic1, Ana Podolski-Renic1, Milica Pesic1, Maria Chiourea2, Jasna Bankovic1, Tijana Andjelkovic1, Vedrana Milinkovic1, Nikola Tanic1, Sarantis Gagos2. 1University of Belgrade, Institute for Biological Research, Belgrade, Serbia, 2Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece.
Molecular Basis Of Aberrant Expression Of Alkaline Phosphatase In Renal Brush Border Membrane From Renal Cell Carcinoma Patients. Ujjawal Sharma, Sarwan Kumar Singh, Rajendra Prasad. Postgraduate Institute of Medical Education and Research, Chandigarh, UT, India. *Unable to present poster due to unforeseen circumstances.
Molecular basis of oncogene cooperation in liver cancer. Asha Balakrishnan1, Lionel Lim1, Stefano Cairo2, Sanjay Chandriani1, Kirk D. Jones1, Marie-Annick Buendia2, Andrei Goga1. 1University of California, San Francisco, CA, 2Institut Pasteur, Paris, France.
Oncogenic MCT-1 upregulates EGFR expression through YY1 transcription factor that cooperatively prevents apoptosis. Tai-Du Lin, Hsin-Ling Hsu. National Health Research Institutes, Taiwan, Taiwan.
OncoPredictor: An integrative genomics platform to systematically predict responsive tumor populations from in vitro drug response data. Daniel R. Rhodes1, Gary Daubresse1, Peter Wyngaard1, Mark Tomilo1, Paul Williams1, Christine O'Day2, Yulia Ovechkina2, Usha Warrior2, Seth Sadis1. 1Compendia Bioscience, Ann Arbor, MI, 2Ricerca Biosciences, Bothell, WA.
PALB2-KEAP1 interaction links oxidative stress to cancer and Fanconi anemia. Jianglin Ma, Bing Xia. The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, UMDNJ, New Brunswick, NJ. *Unable to present poster due to unforeseen circumstances.
PDL192, a humanized antibody to TweakR exhibits potent anti-tumor activity in pancreatic cancer models. Bonnie L. Hylander1, Donghee Choi2, Mien Sho2, Debra T. Chao2, Gary C. Starling2, Patricia A. Culp2, Elizabeth A. Repasky1. 1Roswell Park Cancer Institute, Buffalo, NY, 2Facet Biotech, Redwood City, CA.
Pleiotropic Effects of Simvastatin on Prostate Tumor Growth and Metastasis. Samith T. Kochuparambil1, Belal Al-Husein2, Anna Goc2, Sahar Soliman2, Mrunal Choudhary2, Junxiu Liu2, Payaningal R. Somanath2. 1Medical College of Georgia, Augusta, GA, 2University of Georgia, Augusta, GA.
Potential for patient tailoring for prodrug of gemcitabine (LY2334737) by assessment carboxylesterase II expression in solid tumor biopsies. Timothy R. Holzer1, Kathleen Heinz-Taheny1, Darryl W. Ballard1, Eric L. Powell1, Marisa P. Dolled-Filhart2, Jason Christiansen2, Mark Gustavson2, Jennifer Biryukov2, Jagatheswari Virayah1, Susan E. Pratt1, Robert L. Shepard1, Sara C. Durland-Busbice1, Anne H. Dantzig1. 1Eli Lilly & Co., Indianapolis, IN, 2HistoRx, New Haven, CT.
Probing the effects of linker flexibility in second mitochondria derived activator of caspases mimetic dimers and assessing their ability to induce apoptosis in a MDA-MB-231 cell line. Taz Cheema1, Robert Ben1, Herman Cheung2, Eric LaCasse2. 1University of Ottawa, Ottawa, ON, Canada, 2Childrens Hospital of Eastern Ontario, Ottawa, ON, Canada.
Proliferative suppression of anthraquinone derives, emodin and aloe-emodin, through selective targeting in prostate and breast cancer cells. Pao-Hsuan Huang, Ho Lin. National Chung Hsing University, Taichung, Taiwan.
Restoring sensitivity to anti-EGFR based therapy in lung adenocarcinoma by downstream modulation of the FOXO1/KLF6 transcriptional network. Jaya Sangodkar1, Suzanna Katz1, Tara Albano1, Heather Melville1, David Burstein1, Katerina Politi2, Analisa Difeo1, Goutham Narla1. 1The Mount Sinai School of Medicine, New York, NY, 2Memorial Sloan-Kettering Cancer Center, New York, NY.
Sequence analysis of HSP90-encoding genes in breast tumor tissue identifies a novel 9 bp deletion in HSP90AB1. David I. Lichter1, Hadi Danaee1, Olga Tayber1, Michael Sintchak1, Keiske Kuida1, Josephine M. Atienza2, Hiroshi Miyake3, Stephen J. Blakemore1. 1Millennium: The Takeda Oncology Company, Cambridge, MA, 2Takeda San Diego, Inc., San Diego, CA, 3Takeda Pharmaceutical Company Ltd., Osaka, Japan.
TAZ as a regulator of mesenchymal transformation and clinical aggressiveness in gliomas. Katrina Salazar1, Veerakumar Balasubramaniyan2, Brian Vaillant1, Faith Hollingsworth1, Kristin Diefes1, Dimple Patel1, Krishna Bhat1, Ken Aldape1. 1UT M. D. Anderson Cancer Center, Houston, TX, 2University Medical Center Groningen, Groningen, Netherlands Antilles.
TGF-β blockade improves the distribution and efficacy of chemotherapeutic agent in breast carcinoma. Jieqiong Liu, Shan Liao, Yuhui Huang, Rakesh K. Jain, Lei Xu. Massachusetts General Hospital, Boston, MA.
The role of LKB1 as a tumor suppressor in esophageal squamous cell cancer. Ching Tzao1, An-Li Hsueh2, Ban-Hen Chen1, Yaw-Wen Guo2, Guang-Guan Sun1, Shih-Chun Lee1. 1Tri-Service General Hospital, Taipei, Taiwan, 2National Defense Medical Center, Taipei, Taiwan.
The short-term effects of arsenic on Cdk5-dependent apoptosis of prostate cancer cells. Mei-Chih Chen1, Paulus S. Wang1, Ho Lin2. 1National Yang Ming University, Taipei, Taiwan, 2National Chung Hsing University, Taichung, Taiwan.
Therapeutic response in primary glioblastoma neural stem cells relative to patient-matched non-stem tumor cells. Shaun D. Fouse, Bell Robert, Sara Downey, Jean Nakamura, Susan Chang, Joseph F. Costello. University of California, San Francisco, CA.